Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Psyadon Pharma
• Treatments: Ecopipam

Criteria

Inclusion Criteria:

• Subject must be diagnosed with Pathological Gambling according to DSMIV criteria

• Subject must have at least 2 episodes of gambling behavior within the previous 2 weeks before screening

• Subject must have gambling urges of at least moderate intensity

Exclusion Criteria:

• Subjects must not have unstable medical illness or clinically significant abnormalities on lab tests, ECG, or physical exam

• Subjects with major depressive episode within the last 2 years

• Subjects with a history of attempted suicide

• Subjects with first degree relative with major depressive episode that resulted in hospitalization, attempted or completed suicide

• Subjects with a history of epilepsy or seizures

• Subjects with a myocardial infarction (heart attack) with in the last 6 months

• Subjects with a lifetime history of bipolar disorder, dementia, schizophrenia, or any psychotic disorder

• Subjects with current of recent DSM-IV diagnosis of substance abuse or dependence (with the exception of nicotine)